Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine

1

MEDI0618 is a fully humanized monoclonal antibody targeting PAR2, showing potential for migraine prevention.
2

The antibody demonstrated high affinity for human PAR2 and effectively inhibited calcium increase in various cell types.
3

In preclinical models, MEDI0618 prevented migraine-like pain induced by multiple triggers, including nitroglycerin and mast cell degranulation.
4

Unlike CGRP receptor antagonists, MEDI0618 effectively reduced pain in models independent of CGRP signaling.
5

MEDI0618 did not alleviate post-traumatic headache symptoms, indicating its specificity for migraine-related mechanisms.

Brain

by Caroline M Kopruszinski, John E Linley, Peter Thornton, Alison S Walker, Philip Newton, Sadhana Podichetty, Radhey Hemendra Ruparel, Luiz Henrique Moreira de Souza, Edita Navratilova, Guy Meno-Tetang, Ian Gurrell, David W Dodick, Claire Dobson, Tharani Chessell, Frank Porreca, Iain Chessell
February 28, 2025

1